A clinical research of short-cycle repeat transurethral resection combined pirarubicin treatment of T2 invasive bladder cancer

Fei LI; Guofei Zhang; Wei Deng; Junjie MA; Zhen Yan; Yue WU

Return

A clinical research of short-cycle repeat transurethral resection combined pirarubicin treatment of T2 invasive bladder cancer

VernacularTitle:短周期重复电切联合吡柔比星治疗 T2期移行膀胱癌的临床研究
Author: Fei LI ; Guofei ZHANG ; Wei DENG ; Junjie MA ; Zhen YAN ; Yue WU
Publication Type:Journal Article
Keywords: Urinary bladder neoplasms/TH; Electrosurgery/MT; Urethra/SU; Doxorubicin/AA/A
From: Journal of Chinese Physician 2015;(3):351-353
CountryChina
Language:Chinese
Abstract: Objective To investigate the short-cycle repeated transurethral resection ( Re-TURBT) combined pirarubicin treatment of T2 muscle invasive bladder tumor efficacy and safety.Methods From October 2010 to December 2013, 56 clinically diagnosed cases of bladder cancer were divided into two groups;the experimental group was taken a short-cycle repeat transurethral resection surgery, and the con-trol group taken along open surgery to remove the tumor and its surrounding 2cm bladder tissue, postopera-tive patients were given pirarubicin infusion therapy.Results Each patient completed the trial.For the ex-perimental group, blood loss and operative time was significantly lower than the control group ( P <0.05). For experimental group after 3 months, 6 months, and 12 months, maximum bladder capacity ( MBC) and patient perception of bladder condition ( PPBC) were significantly higher than control group ( P <0.05 ) . For experimental group after 3 months and 6 months, maximum urinary flow rate ( Qmax) was significantly higher than control group ( P <0.05) , but no significant difference between two groups at 12 months.The incidence of adverse events, vascular endothelial growth factor ( VEGF) , and a total recurrence rate showed no significant difference ( P >0.05).For experimental group, bladder perforation in 1 case, 1 case was forced to open surgery, the incidence rate was about 6.7%.Conclusions The short-cycle repeated trans-urethral resection combined pirarubicin treatment of T2 invasive bladder tumor was simple, effective and se-curity.